What is the purpose of this trial?
The primary objective of this study is to assess the rates of HIV-1 seroconversion in Men (MSM) and transgender women (TGW) who have sex with men and who are administered daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir DF (F/TDF) with a minimum follow-up of 48 weeks and at least 50% of participants have 96 weeks of follow-up.
Ages: 18 years and older
Dates: 12/01/2016 - 02/28/2019
Last Updated: 02/09/2017
Study HIC#: 1608018342